John J. Castellani is President and Chief Executive Officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), an organization that represents America’s leading biopharmaceutical research companies. The biopharmaceutical sector directly employs over 650,000 Americans working to develop new medicines that help patients fight disease and live, longer healthier lives.Read More
The Catalyst Contributors
Authors Contributing to The Catalyst
The Catalyst provides news and commentary on access to life-saving treatments, America’s biopharma industry and researchers’ progress in developing new medicines.
The Catalyst is edited by Kaelan Hollon, Senior Director of Communications at PhRMA. Contributors include PhRMA staff and leaders from the industry.
Jon Tripp is Senior Director of Digital Advocacy in the Communications & Public Affairs department at PhRMA where he oversees the organization’s widespread online presence. He came to PhRMA in 2005 after serving as Deputy Communications Director for the U.S. House of Representatives Committee on Energy and Commerce.
Jon enjoys spending every free moment with his wife and three kids - and their King Charles Cavalier (Lady). Despite all the Apple devices he carries on his person, Jon neither works for the retailer nor draws referrals for his ardent support of their products.Read More
Stephanie is a Senior Director of Communications at PhRMA, focusing on regulatory issues and intellectual property. As a rare disease patient and stroke survivor, she is very passionate about the need for public policy that encourages innovation and the development of safe and effective new therapies. In her free time, she is trying her hand at gardening and decorating her relatively-new home (while trying to keep two kittens from breaking anything else).Read More
Sascha Haverfield is the Vice President for Scientific and Regulatory Affairs at PhRMA. He leads PhRMA's activities on global regulatory policy issues and is the architect of our engagement on the implementation of the Prescription Drug User Fee Act (PDUFA). He previously worked in the biopharmaceutical industry on drug discovery, translational medicine and regulatory affairs with a focus on global drug development issues.Read More
Randy Burkholder is Vice President of Policy at the Pharmaceutical Research and Manufacturers of America. Randy is a former member of the Board of Directors of the Personalized Medicine Coalition and has over 17 years experience in health care policy, advocacy and communications in the medical technology and pharmaceutical industries. In his free time, Randy may be found coaching youth basketball, fishing in his native Virginia, or writing clever witticisms for his blog bio.
Jenni Brewer came to PhRMA with nearly a decade of colorful public affairs experience. Her work pursuits have landed her in turkey farms, NASCAR races, and even a Civil War fort. A proud Virginian, she graduated from the College of William & Mary and never misses an opportunity to return to Williamsburg to bump elbows with the colonials. In her free time she could be caught knitting, crocheting or partaking in other crafty endeavors.Read More
Dr. Bill Chin leads PhRMA’s Scientific & Regulatory Affairs department. A physican, an endocrinologist and an academic at heart, Dr. Chin envisions establishing PhRMA as the premiere convener in advancing drug discovery and development, regulatory sciences and collaborative partnerships.Read More
Christian has been a member of the PhRMA family for 12 years. In that time, he has helped create programs to assist the uninsured and promote the value of innovative jobs. Currently, he proudly leads PhRMA’s social and digital team. When not staring at his computer screen, he’s a devoted dad, struggling pianist and amateur triathlete. Follow Christian on Twitter @CCatPhRMARead More
Kaelan Hollon joined PhRMA in 2007, coming from a public relations firm in Louisville, Kentucky. She previously worked for a small law firm that handled bioethics consulting, and while in Louisville she managed several health care accounts for lobbying and public affairs clients. She graduated from Eastern Kentucky University with a degree in Philosophy and has a J.D. from the University of Kentucky. In her spare time, she competes nationally as a professional boxer. Follow Kaelan on Twitter @KaelanAtPhRMA
Jeff Trewhitt is a 23-year PhRMA veteran and two-time cancer survivor who understands at both personal and professional levels the importance of sustaining the world-leading innovation of America’s biopharmaceutical research companies. A former journalist who once covered the Food and Drug Administration, National Institutes of Health and biopharmaceutical companies, he has dealt with industry issues for more than three decades.Read More
Karl Uhlendorf joined PhRMA more than seven years ago, making the leap from journalism to communications. He spent the previous baker’s dozen at Elsevier/FDC Reports, covering regulatory, policy and business developments specific to the biopharma, med-tech and consumer health sectors. Married with three very active young children, he enjoys travel, good food, and the past travails and recent glories of New England sports teams. Follow Karl on Twitter @KUhlendorf.Read More
Josie Martin is Executive Vice President of Public Affairs at PhRMA. In a career spanning over 20 years, she worked on the Senate Finance Committee, The American Red Cross and has touched many facets of healthcare communications, from anti-smoking campaigns and getting America fit to cancer awareness.Read More
Nearly seven years ago, Jennifer Wall left Capitol Hill and started doing media advocacy for PhRMA. After gaining invaluable experience while working as a communications staffer for the Homeland Security Committee and Speaker of the House, she decided to venture into new territory and explore other issues of interest to the country – biopharmaceuticals, innovation, and healthcare policy. She graduated from the University of Minnesota with a degree in political science and is still wondering to this day how she survived the cold. In her free time, she takes her baby girl on long walks andRead More
Preet Bilinski arrived at PhRMA nine years ago, after graduating from James Madison University. Somehow her degree in Computer Information Systems landed her in the healthcare communications world. She manages the Medicines in Development series, that showcases the hope and promise of innovative treatments. In her spare time, she’s trying to keep her puppy, Jake from eating her out of house and home.Read More
Salvatore (“Salvo”) Alesci, M.D., Ph.D. joined PhRMA in December 2011 as Vice President, Scientific & Regulatory Affairs. In this role, Dr. Alesci serves as the primary expert for PhRMA on scientific and medical issues. He carries overall responsibility for establishing PhRMA as a “go to” source for input on policies and legislation related to innovative approaches to biopharmaceutical discovery and development. Dr. Alesci brings to PhRMA over ten years of combined academia/government/industry research experience and multi-disciplinary expertise in Translational Medicine.Read More
Richard I. Smith is a past Executive Vice President for Policy and Research at the Pharmaceutical Research and Manufacturers of America (PhRMA).
Previously, Rick was Vice President, Public Policy and Research at the American Association of Health Plans; Vice President, Health Policy at the Association of Private Pension and Welfare Plans (now the American Benefits Council); Director, Public Policy at the Washington Business Group on Health (now the National Business Group on Health); and Staff Director of the Maryland Governor’s Commission on Health Care Policy and Financing.Read More
Chester “Chip” Davis, Jr. currently serves as Executive Vice President for Advocacy at PhRMA. In this role Davis is responsible for leading and managing PhRMA’s federal, state and international government relations and advocacy efforts.Read More
Kristin Van Goor is Assistant Vice President of Scientific and Regulatory Affairs at PhRMA. She leads PhRMA’s activities on regulatory and science policy issues ranging from innovative biologics and biosimilars, information technology, benefit-risk assessment, and patient-focused drug development. Kristin is a geneticist by training, having received her doctorate from Yale University and completing a postdoctoral fellowship in the Cancer Genetics Branch of the National Human Genome Research Institute. When away from the office, she enjoys dancing, improving her skills at pairing wine andRead More
Mr. Hugin serves as Chairman and Chief Executive Officer of Celgene Corporation, a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for unmet medical needs in cancer and immune-inflammatory disease. He joined Celgene in June 1999 and has been a Director of Celgene since December 2001. Mr. Hugin also serves as a Director of The Medicines Company, Atlantic Health System, Inc. and of Family Promise, a national non-profit network assisting homeless families.Read More
John B. Crosby, J.D. became the executive director of the American Osteopathic Association (AOA) in May 1997. Prior to joining the AOA, he spent six years at the American Medical Association (AMA) as senior vice president for health policy where he was actively involved with policy development and strategic planning.Read More
John C. Lechleiter, Ph.D., chairman, president and CEO of Eli Lilly and Company, was elected chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA) on April 13, 2012.Read More
Jeff Francer is Vice President and Senior Counsel at PhRMA and serves as principal counsel to the association on issues relating to the research, development, and regulation of medicines in the US and globally. Prior to joining PhRMA, Jeff served as Associate Chief Counsel of the FDA and as a regulatory attorney for biopharmaceutical companies. Jeff is also an avid Red Sox fan.Read More
Dr. Kucherlapati is the Paul C.Cabot Professor in the Harvard Medical School Department of Genetics. He is also a professor in the Department of Medicine at Brigham and Women's Hospital. Dr. Kucherlapati was the first Scientific Director of the Harvard Medical School-Partners Healthcare Center for Genetics and Genomics. His research focuses on gene mapping, gene modification, and cloning disease genes. During 1989-2001, Dr.Read More